Beta Finch - Income & Dividends - EN

Beta Finch
  • 0.0 (0)
  • Investing

Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.

  1. 8h ago

    Altria Q3 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: INCOME (https://betafinch.com/groups/INCOME) ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Altria's third quarter 2026 results, and there's a lot on the table — from a lawsuit against the FDA to a brand-new flavor lineup for nicotine pouches. I'm Alex, here with Jordan, and we're going to break it all down for you. **JORDAN:** Before we get into it — quick reminder, Alex, you know the drill. **ALEX:** Right, right. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Perfect. Okay, let's get into Altria's numbers. **ALEX:** So headline first: adjusted diluted EPS grew 4.8% in Q3, and 5.1% through the first nine months of the year. That's solid growth for a company that's often thought of as slow and steady. **JORDAN:** And here's the thing that jumped out at me — they actually raised guidance. Full-year adjusted EPS is now expected between $5.66 and $5.74, which works out to 4.5% to 6% growth off last year's $5.42. That's up from their original range of 2.5% to 5%. So management is feeling pretty confident here. **ALEX:** Yeah, and that confidence is coming largely from the smokeable products segment, which is still the earnings engine for Altria. Adjusted operating company income there grew 3.9% to $3.1 billion in the quarter. Margins expanded too, up to 64.5%. **JORDAN:** What's interesting is how they're doing it. This isn't just pure pricing power — it's a "total portfolio" strategy. Marlboro's holding the premium end, but they've also got Basic gaining share in the discount segment. Basic's retail share jumped 1.8 points year-over-year as more price-pressured smokers trade down. **ALEX:** And then there's the new kid — Marlboro Cowboy Cut. It's basically a lower-priced premium option designed to keep value-conscious Marlboro smokers in the franchise instead of losing them to discount brands entirely. It's already in about 100,000 stores, roughly 75% of cigarette volume nationally. **JORDAN:** Smart playbook, honestly. They've done this before with Marlboro Special Select and Marlboro Black — launch at an introductory price, then gradually take pricing up over time once it's established. And it seems to be working — Marlboro's share of the premium segment hit 60%, up slightly both year-over-year and sequentially. **ALEX:** Now let's talk about the smoke-free side of the business, because this is where things get really interesting strategically. On! nicotine pouches — shipment volume was up 13.3% in the quarter to 47.8 million cans. **JORDAN:** But retail share only ticked up 0.1 point year-over-year, and was actually down 0.3 sequentially. That tells you this category is getting fiercely competitive. Everybody's throwing flavors and higher nicotine strengths at the wall right now. **ALEX:** Which is exactly what Altria's subsidiary Helix is doing in response — they just rolled out on! PLUS 12-milligram nationally, and they're adding new flavors: Blueberry Mint and Mango Pineapple hit shelves this month, with Watermelon Mint coming in November. **JORDAN:** And don't sleep on the marketing push either — they hosted something called the "on!vitational," an invite-only golf tournament in Palm Beach. It's meant to be a recurring, multiyear brand platform. Altria's clearly trying to build lifestyle equity around on!, not just compete on nicotine strength and flavor. **ALEX:** Now, here's the part of this call I found most newsworthy — the regulatory fight. Altria's Helix and NJOY subsidiaries actually sued the FDA this quarter. **JORDAN:** Yeah, this is a big deal. The lawsuit is asking a court to force the FDA to stick to the 180-day review timeline that Congress set for product authorizatio This episode includes AI-generated content.

  2. 2d ago

    Coca-Cola Q3 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME) ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're cracking open Coca-Cola's third quarter 2026 results. KO had some really interesting numbers to unpack this quarter. **JORDAN:** Yeah, there's a lot here — strong volume, raised guidance, and some big structural changes brewing for next year. Should be a good one. **ALEX:** Before we dive in, just our standard reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Solid. Okay, let's get into it. **ALEX:** So headline numbers first. Coca-Cola posted 5% unit case volume growth and 7% organic revenue growth for Q3. That's genuinely strong, especially on top of a strong first half. Comparable EPS came in at $0.91, up 11% year-over-year, though two points of that was currency tailwind. **JORDAN:** And here's the thing that stood out to me — they actually RAISED full-year guidance. They're now expecting organic revenue growth of at least 5%, and comparable EPS growth of at least 11% versus the $3 base from 2025. Free cash flow guidance also moved up to at least $13 billion for the year. **ALEX:** Right, and the balance sheet is in great shape too — net debt leverage at 1.3 times EBITDA, which is actually below their target range of 2 to 2.5 times. CFO John Murphy used this word "optionality" a lot on the call, which I think is code for "we're sitting pretty and waiting to see what happens with that IRS case." **JORDAN:** That IRS dispute keeps popping up as kind of the elephant in the room. They're not giving specifics, but they're clearly positioning the balance sheet to handle whatever outcome comes down — best case or worst case. **ALEX:** Let's talk margins for a second, because that's where some real execution shows up. Comparable gross margin expanded about 170 basis points, operating margin up 110 basis points. And importantly — margin expansion didn't come at the cost of investment. They actually ramped up marketing spend, double-digit growth in above-the-line investment. **JORDAN:** That "more with more" philosophy Lauren Lieberman from Barclays asked about — basically, Coke's saying we can grow margins AND keep pouring money into brand building at the same time. That's not easy to pull off, so I think that's a genuine positive signal for the quality of this growth. **ALEX:** Now let's talk geography, because this is really a tale of different markets doing different things. North America was actually flat on volume — which sounds concerning at first — **JORDAN:** — but context matters here. That flatness was largely due to July 4th holiday timing shifting into Q2, plus they're cycling really strong prior-year comps on Topo Chico and BODYARMOR. Management pointed out volume actually improved sequentially each month through the quarter. And get this — Mr. Pibb posted another quarter of double-digit growth. Small brand, but a fun data point. **ALEX:** Meanwhile, emerging markets are carrying a lot of weight. Brazil was strong, India had all ten of its top brands growing double digits, and Africa delivered high single-digit volume growth despite tough comparisons. Mexico and Argentina remain challenging, but management says they're seeing encouraging progress. **JORDAN:** China's an interesting one — "subdued" consumer environment, cautious spending, soft domestic demand — but Coke still grew volume there, leaning hard into digital commerce and emerging channels to find growth even when the broader consumer isn't spending freely. **ALEX:** Let's talk about the Q&A, because there were some really pointed questions. Chris C This episode includes AI-generated content.

  3. Oct 22

    Procter & Gamble Q1 2027 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME) ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into Procter & Gamble's fiscal Q1 2027 results — reported October 22nd. Before we dive in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** And honestly, Alex, this is a fun one. P&G doesn't usually give us "volume up 2.4%, organic sales up 4%" headlines — that's the kind of growth they haven't posted together since like 2022. **ALEX:** Exactly. Let's set the scene. Organic sales grew 4.0% — and this is the first quarter they're reporting that number to one decimal place, by the way, a small disclosure change. Volume contributed 2.4 points of that growth, pricing added 0.4 points, and mix added over a point. The headline here is that this is volume-led growth, not price-led. **JORDAN:** Which matters a lot right now. In this consumer environment, growing because more people are buying your stuff — not just because you raised prices — that's the better kind of growth story. **ALEX:** All ten product categories grew. All six geographic regions grew. North America was up 3%, Europe up 4% with the UK leading at high-single-digits, and Greater China was the standout at 8% growth, driven by SK-II up 12% and Pampers up nearly 50%. **JORDAN:** That Pampers number in China is wild, but CFO Andre Schulten was upfront that it's partly benefiting from a competitor stumbling in that market. Take out that tailwind and China's still growing mid-single-digits organically, which on its own is a great result given how soft Chinese consumer sentiment has been. **ALEX:** Now let's talk bottom line. Core EPS came in at $2.00, up about 1% year-over-year, flat on a currency-neutral basis. Gross margin was actually down 150 basis points, operating margin down 80 basis points. **JORDAN:** And here's the tension in this quarter — productivity improved a strong 250 basis points, but that got eaten up by rising commodity costs, freight, and continued marketing investment. Schulten flagged that commodity headwinds are only going to get worse from here. **ALEX:** Right, let's talk about that number because it's a big one — $1.4 billion after-tax commodity cost headwind for the full fiscal year. That's tied to oil, assuming Brent crude around $100 a barrel. And when you add in currency headwinds, higher interest expense from recent M&A, and lower non-operating income, the total headwind below the operating line balloons to about $1.9 billion after tax, or $0.79 a share — that's 11% of last year's core EPS. **JORDAN:** And what's notable is they only felt about 5% of that commodity hit in Q1, with 8% guided for the full year. So Schulten was basically telling investors: brace for Q2, because that's when the bigger chunk of this flows through the income statement. **ALEX:** Speaking of guidance — despite all that cost pressure, P&G held its full-year guidance ranges. Organic sales growth of 1% to 3%, though they're clearly running ahead of that right now. Core EPS growth of 0% to 3%, landing between $6.89 and $7.11 a share. They did raise the all-in GAAP sales outlook, but that's just to reflect the Thorne acquisition, which closed in early October. **JORDAN:** Thorne is interesting — that's the wellness and supplements brand. Management was clear on the call that they want Thorne's existing team to keep leading the business, with P&G playing a supporting role on things like international expansion and supply chain, not a full-on integration. **ALEX:** They also reaffirmed free cash flow productivity guidance of 85-90%, and plan to re This episode includes AI-generated content.

  4. Oct 21

    Philip Morris International Q3 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: INCOME (https://betafinch.com/groups/INCOME) ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Philip Morris International's third quarter 2026 results. This one's got a little bit of everything — record profits, a big strategic pivot in the U.S., and some real geopolitical headwinds. Before we jump in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Okay Alex, let's start with the headline numbers because they're honestly pretty strong. PMI posted organic net revenue growth of 7.1% in Q3, hitting $11.4 billion. Adjusted operating income crossed $5 billion for the first time ever, and margins hit almost 45%. **ALEX:** That's a big one. And EPS came in at $2.36, a new quarterly record, up about 6% excluding currency effects. So on the surface, this is a "records across the board" quarter. **JORDAN:** Right, but there's nuance. CFO Massimo Andolina was pretty transparent that full-year guidance is now trending toward the middle-to-lower half of their ranges — both for operating income growth and EPS growth. And it's not because the core business is struggling. It's really two things: geopolitical cost pressure from the Middle East and Ukraine conflicts, and a massive, intentional investment surge in the U.S. **ALEX:** Let's talk about the smoke-free story first, because that's really the heart of PMI's whole transformation. Smoke-free products now make up 40% of total revenue, and in over 30 markets, they're already more than half of revenue. IQOS, their heated tobacco brand, saw adjusted in-market sales growth accelerate to 7.1% — or over 10% if you strip out Japan and Poland, which both have unique headwinds right now. **JORDAN:** Japan's going through this bumpy excise tax transition — they raised taxes twice this year on heated tobacco specifically, which caused some pantry-loading distortions in the data. Poland's dealing with a flavor ban. But outside those two, the growth story is honestly remarkable — double-digit IMS growth in Italy, Greece, Spain, Germany, the Netherlands, UK. And get this — their international heated tobacco and cigarette combined market share crossed 30% for the first time ever. **ALEX:** And then there's VEEV, their e-vapor brand — shipments up 62% in the quarter, becoming the number one closed pod brand in Europe. That's a smaller piece of the pie but growing incredibly fast. **JORDAN:** Now let's get into the part everyone's really watching — the U.S. and ZYN. This is where it gets interesting, and honestly, a little messy in the near term. **ALEX:** So ZYN had a rough patch earlier this year with volume growth below the category rate. Management's answer was a two-pronged strategic overhaul. First, they're massively expanding the product lineup — new flavors, new nicotine strengths including ZYN Ultra at 9 and 11 milligrams — basically chasing consumers who'd drifted to competitors for higher-nicotine options. **JORDAN:** And it seems to be working — they said category offtake share increased about 1.4 points from June to September. But the second piece is the bigger deal: they're repositioning pricing by moving their flagship cans from 15 pouches to 20 pouches at the same price. Andolina called it a value proposition improvement for consumers, but mathematically, that's roughly a 25% cut in revenue per pouch. **ALEX:** That's a huge deal. And combined with the step-up in marketing spend — U.S. SG&A hit around $370 million in Q3 with another 10% sequential jump expected in Q4 — the company is basically telling investors: expect U.S. profitability to be near zero or even slightly negative next quarter. ** This episode includes AI-generated content.

  5. Oct 21

    Abbott Laboratories Q3 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE), INCOME (https://betafinch.com/groups/INCOME) ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex. **JORDAN:** And I'm Jordan. We've got a genuinely big one today — Abbott Laboratories dropped some major news alongside their Q3 numbers. **ALEX:** We'll get to that in a second, but first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** With that out of the way, Alex, let's start with the headline because it's not every day a 138-year-old company announces it's splitting itself in two. **ALEX:** Right — Abbott announced it's spinning off its entire nutrition business into a standalone, publicly traded company by the end of 2027. We're talking about Similac, PediaSure, Ensure, Glucerna, Pedialyte — the whole $8.5 billion nutrition empire, 16,000 employees, 14 manufacturing sites. CEO Robert Ford said this would actually be the largest pure-play healthy nutrition company in the world, and they expect it to qualify for S&P 500 inclusion on its own. **JORDAN:** And the CEO pick is interesting too — Daniel Salvadori, who's run their Established Pharma and Nutrition division, is taking the reins of the new company. Ford called his team "battle-tested," which, if you've followed Abbott's infant formula saga the last few years — recalls, litigation, supply shortages — that's not an exaggeration. **ALEX:** The strategic logic here is basically: nutrition used to be a healthcare-professional-driven category, now it's a consumer wellness category, and those two worlds need different playbooks, different investment cycles, different marketing muscle. Ford's view is both companies do better focused and independent rather than living under one roof. **JORDAN:** And for shareholders, it's structured as a tax-free spin — you'll own shares of both companies when it's done. Abbott's also planning to have the new nutrition company raise some debt, with proceeds flowing back to Abbott, and both companies will maintain investment-grade ratings. **ALEX:** What's the math on what's left behind? Because that's really the investor question here. **JORDAN:** Right, this is the key number. CFO Phil Boudreau said stripping nutrition out of the current portfolio, Abbott's remaining business — MedTech, Diagnostics, Established Pharma — would see sales growth accelerate by 50 to 100 basis points, gross margin expand by over 200 basis points, and operating margin up roughly 100 basis points. So the pitch is: a leaner, faster-growing, higher-margin Abbott emerges on the other side. **ALEX:** Now let's talk actual Q3 results, because they were solid. Sales grew 7%, EPS grew 9% — both numbers accelerating from the first half of the year. Adjusted EPS came in at $1.42, right in line with guidance and consensus. **JORDAN:** Breaking it down by segment — Diagnostics grew 6.5%, with Core Lab up 5.5% on strong demand across the U.S., Europe, Japan, and Latin America. But the real story there is Cancer Diagnostics, up 14%, largely thanks to the Exact Sciences integration — that's Cologuard. They also just launched their first blood-based colorectal cancer screening test in September, making Abbott the only company offering both stool-based and blood-based options. **ALEX:** Nutrition — even as it heads for the exit — actually had a good quarter. Sales up 5%, broad-based across all four categories. Pediatric nutrition was the standout at 9% growth, helped by those WIC contract wins that let Abbott reclaim market leadership. **JORDAN:** Medical Devices grew 8%, led by electrophysiology and rhythm management, both posting double-digit growth. The Volt PFA catheter is gaining serious traction after its This episode includes AI-generated content.

  6. Oct 20

    3M Q3 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: INCOME (https://betafinch.com/groups/INCOME), INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into 3M's third quarter 2026 results, reported October 20th. This is a loaded one, folks — strong numbers, a major Amazon partnership, and a lot of forward-looking commentary on 2027. Before we get into it, though, the standard reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And honestly, Alex, there's a lot to unpack here. 3M stock jumped over 5% on this print, so let's figure out why. ALEX: Let's start with the headline numbers. Organic growth of 3.3% for the quarter, operating margin of 26.2% — up 110 basis points year-over-year — adjusted EPS of $2.50, up 12%, and free cash flow of $1.2 billion. They returned $600 million to shareholders, split between dividends and buybacks. JORDAN: And importantly, they raised full-year EPS guidance to $9.10-$9.15, up from the prior range. That's roughly 11-12% growth for the year. Management also reaffirmed they expect organic growth above 3.5% for 2026, with Q4 actually accelerating to over 4%. ALEX: That acceleration story is interesting because it's backed by real data — backlog was up high-teens year-over-year heading into Q4, and orders grew high single digits in the quarter. That's not just hopeful talk, that's visibility. JORDAN: Right, and CFO Anurag Maheshwari broke down where the margin expansion is coming from — gross margins were up 230 basis points, driven by procurement savings, better quality control, and higher factory utilization. They've closed 16 manufacturing sites this year already, with 10 more targeted over the next year. That footprint simplification is expected to keep paying off well beyond 2027. ALEX: Now let's get to the part everyone's been buzzing about — Expanded Beam Optical, or EBO. This is 3M's connector technology for AI data center infrastructure. JORDAN: This is the big one. They filed an 8-K the night before the call announcing they issued Amazon a warrant for up to 3.2 million shares — about 0.6% of 3M's stock — tied to Amazon hitting $6 billion in cumulative purchases of optical connectivity and data-center-related products over seven years, plus other milestones. ALEX: CEO Bill Brown was careful to frame this as strategic validation rather than a guaranteed revenue stream. He emphasized there's no firm volume commitment — 3M has to "earn the right" to that business. But symbolically, locking in a warrant structure with Amazon, on top of the previously announced Microsoft Azure partnership, signals real traction with hyperscalers. JORDAN: And they paired that with a manufacturing deal — a contract agreement with Genius Electronic Optical, or GSEO, plus taking a 4.7% equity stake in that company to secure supply chain capacity. 3M's doubling its internal ferrule manufacturing capacity, and GSEO can reportedly scale multiples beyond that. ALEX: Sizing it for listeners — EBO revenue this year is around $40 million. Management expects that to roughly double next year, maybe a bit more. They've pegged the total addressable market at around $2 billion by 2028. So it's small today, but the growth trajectory and the ecosystem-building — they mentioned a Multi-Source Agreement that's grown from 17 to 63 member companies — suggests this could become a meaningful growth vertical. JORDAN: Let's talk segments for a second, because the picture is mixed. Safety & Industrial had a standout quarter, up 7% organically, driven by commercial excellence and new product ramp. Transportation & Electronics was basically flat at 0.5%, dragged down by co This episode includes AI-generated content.

  7. Oct 15

    Johnson & Johnson Q3 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're diving into Johnson & Johnson's third quarter 2026 results, reported Tuesday. Before we get going, a quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And there's a lot to unpack here, Alex, because on the surface this looks like a messy quarter, but underneath it's actually a pretty strong one. ALEX: Right, let's start with the headline numbers. J&J posted $25.4 billion in revenue for Q3, up 6% operationally, which actually beat analyst expectations. Management raised full-year guidance and now expects full-year operational sales growth of 6.7% to 7.1%, putting them on track to cross $100 billion in annual revenue for the very first time in the company's 140-year history. JORDAN: That's a huge milestone. But here's where it gets messy — GAAP net earnings were just $210 million, and diluted EPS came in at nine cents, compared to $2.12 a year ago. That's a massive drop. ALEX: And the reason is a one-time hit, not a business problem. J&J took a $5.5 billion charge tied to resolving the ovarian talc litigation, plus costs from two acquisitions — Firefly Bio in oncology and a collaboration with Cell BioMedicine in cell therapy. Strip those out, and adjusted EPS was $2.59, down about 7.5% year-over-year, but mostly because of those deal-related expenses, not underlying weakness. JORDAN: Exactly. The core business is actually accelerating. Innovative Medicine — that's their pharma segment — grew 7.9% operationally to $16.8 billion, with eight brands growing double digits. Oncology alone grew 17%. ALEX: Let's talk about the stars of the show. Tremfya, their immunology drug, grew 68% in the quarter. CARVYKTI, their multiple myeloma cell therapy, up 35%. And RYBREVANT, for lung cancer, up 64%. Tom Cavanaugh, the head of Innovative Medicine, specifically called out Icotrokinra — their new oral psoriasis treatment — saying it's tracking better than almost any launch they've seen in psoriatic disease, with over 20,000 patients started in just months. JORDAN: What stood out to me is they're calling this a path to double-digit growth by 2030, and when an analyst from Goldman pressed CFO Joe Wolk on whether that assumes big acquisitions, he was pretty direct — no, it's organic. That's a meaningful claim given how reliant a lot of pharma growth stories are on M&A. ALEX: Now, MedTech is the other side of the story, and it's where things got rockier. That division only grew 2.5%, missing expectations. Management was candid about it — Timothy Schmid, who runs MedTech, basically said "our performance is below the standard we set internally." JORDAN: Two specific problem areas: international markets, especially due to disruption from the Middle East conflict affecting hospital purchasing and tender timing, and Abiomed, their heart pump business, which actually declined 1.5% because of a disputed study on high-risk PCI procedures. Execs pushed back hard on that study's methodology. ALEX: But it wasn't all bad news in MedTech. Shockwave, their cardiovascular device business, grew 17%. And they got FDA clearance for Ottava, their new surgical robot — first commercial customer already signed. That's a big long-term bet on competing with Intuitive Surgical in robotics. JORDAN: One housekeeping item investors should note — J&J confirmed they're still on track to spin off their orthopedics business, DePuy Synthes, by mid-2027, and they're leaning toward a straight spin-off rather than a sale. ALEX: Let's hit a couple of Q&A highlights. On Icotrokinra, This episode includes AI-generated content.

  8. Oct 8

    PepsiCo Q3 2026 Earnings Analysis

    More earnings analysis: https://betafinch.com Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into PepsiCo's third quarter 2026 results, reported October 8th. Before we jump in, quick reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And there's a lot to unpack here, Alex, because this is one of those quarters where the headline numbers look fine, but the guidance cut tells a very different story. ALEX: Right, let's start with the numbers. Organic revenue grew 3.1% — that's actually the fastest growth rate PepsiCo has posted since Q4 2023. Reported revenue was north of 5%. Core operating profit was up 3%, and EPS grew 2%. JORDAN: Those top-line numbers are genuinely good news, especially the fact that it was volume-led — global beverage volume up 3%, global snacks volume up 4% excluding a commodity-heavy South Africa grains business. But here's the catch: PepsiCo lowered its full-year EPS guidance, and it's entirely margin-driven. ALEX: Right, so let's split this into the two stories — international, which is firing on all cylinders, and North America, which is clearly the problem child. CFO Steve Schmitt said international organic revenue grew 8% with operating margin expansion of 105 basis points. CEO Ramon Laguarta noted international is now 45% of the company's profit year-to-date. JORDAN: That's a massive shift in the company's center of gravity. Meanwhile in North America, it's a mixed bag. Foods — meaning the Frito-Lay snacks business — actually improved sequentially. Laguarta made a point of saying that last year snacks volume was negative low-single-digits, and this year it's flipped to positive low-single-digit growth. He credits the price reset strategy plus innovation platforms like portion-controlled packs and the "permissible" portfolio — think SunChips, Smartfood, PopCorners, Simply. ALEX: But beverages in North America is where things get ugly. Schmitt said the beverage business actually decelerated in the quarter. Laguarta was blunt about it — he said they're competing well in hydration and energy, pointing to Gatorade, Propel, and the pending integration of Alani Nu and Celsius, but they are explicitly "not competing well" in soft drinks, meaning Pepsi, Mountain Dew, and that whole core carbonated lineup. JORDAN: And that word kept coming up over and over — "urgency." Multiple analysts pushed on what that actually means in practice, because it's easy to say urgency and mean nothing. Laguarta's answer was essentially twofold: cut every cost that isn't tied to growth — overhead, corporate unallocated spending, duplications — and reinvest that money into A&M, advertising and marketing, behind the core brands. He also name-checked a new partnership with Publicis for more data-driven, targeted marketing. ALEX: Now let's talk about why guidance actually got cut, because this is the part investors should really sit with. Schmitt said input costs are trending higher than expected, mix has been a headwind, and — this is a detail that's easy to miss — PepsiCo got a tariff-related benefit in North America beverages in Q3 that won't repeat in Q4. So that's a double hit: inflation ramping as hedges roll off, plus losing a one-time tariff tailwind. JORDAN: And importantly, they're not pulling back on investment to protect the bottom line. Schmitt was explicit that A&M spending actually increased in both international and North America this quarter — double-digit increases in the U.S., in fact. So the margin pressure is a deliberate choice to keep funding growth rather than a sign the business is falling apart. This episode includes AI-generated content.

See All (34)

About

Reliable dividend payers popular with income-focused investors. AI-powered earnings call analysis for Income & Dividends (INCOME). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.

Information